Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

• Status: Unknown status
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hebei Yanda Hospital
• Collaborator: Beijing Tiantan Hospital
• Treatments: Bevacizumab; Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• High grade glioma was diagnosed by post-operation pathological method, and shows a relapse.

• Before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, PET or MRS results show positive features.

• The age of patient should be between 18 years old and 70 years old.

• The condition of the patient permits the treatment of ultra-low dose Bevacizumab plus Temozolomide.

• The patient is informed consent,and willing to join in this research.

Exclusion Criteria:

• The diagnosis is not recurrent high-grade glioma.

• The diagnosis of high-grade glioma was not established by pathological method.

• The results of imageological examinations do not meet the standard of including.

• The age of the patient does not meet the requirement of this research.

• The condition of the patient does not permit the treatment of ultra-low dose Bevacizumab plus Temozolomide.

• There are other conditions that the clinicians believe that the treatment of ultra-low dose Bevacizumab plus Temozolomide is not appropriate for the patient.

• The patient is not willing to join in this research.